{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:41:22Z","timestamp":1792215682430,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-024-01208-4","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T10:01:44Z","timestamp":1715076104000},"page":"185-200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3272-9643","authenticated-orcid":false,"given":"Di","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiye","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikai","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sicong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuofan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8700-7042","authenticated-orcid":false,"given":"Hewei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6750-1465","authenticated-orcid":false,"given":"Hang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lintai","family":"Da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-guang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9210-1823","authenticated-orcid":false,"given":"Sheng-ce","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3091-7712","authenticated-orcid":false,"given":"Ruijiao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9597-2843","authenticated-orcid":false,"given":"Tianlei","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9912-633X","authenticated-orcid":false,"given":"Jiaxu","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2955-7289","authenticated-orcid":false,"given":"Yujia","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"key":"1208_CR1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41578-021-00372-2","volume":"7","author":"GA Roth","year":"2022","unstructured":"Roth, G. A. et al. Designing spatial and temporal control of vaccine responses. Nat. Rev. Mater. 7, 174\u2013195 (2022).","journal-title":"Nat. Rev. Mater."},{"key":"1208_CR2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41591-020-0774-y","volume":"26","author":"DJ Colby","year":"2020","unstructured":"Colby, D. J. et al. Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. Nat. Med. 26, 498\u2013501 (2020).","journal-title":"Nat. Med."},{"key":"1208_CR3","doi-asserted-by":"crossref","first-page":"590780","DOI":"10.3389\/fimmu.2020.590780","volume":"11","author":"T Ng\u2019uni","year":"2020","unstructured":"Ng\u2019uni, T., Chasara, C. & Ndhlovu, Z. M. Major scientific hurdles in HIV vaccine development: historical perspective and future directions. Front. Immunol. 11, 590780 (2020).","journal-title":"Front. Immunol."},{"key":"1208_CR4","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-020-00254-8","volume":"5","author":"DI Bernstein","year":"2020","unstructured":"Bernstein, D. I. et al. The R2 non-neuroinvasive HSV-1 vaccine affords protection from genital HSV-2 infections in a guinea pig model. npj Vaccines 5, 104 (2020).","journal-title":"npj Vaccines"},{"key":"1208_CR5","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw7083","volume":"4","author":"S Awasthi","year":"2019","unstructured":"Awasthi, S. et al. Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes. Sci. Immunol. 4, eaaw7083 (2019).","journal-title":"Sci. Immunol."},{"key":"1208_CR6","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41565-020-0648-y","volume":"15","author":"W Wang","year":"2020","unstructured":"Wang, W. et al. Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. Nat. Nanotechnol. 15, 406\u2013416 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"1208_CR7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nrc.2018.13","volume":"18","author":"RBS Roden","year":"2018","unstructured":"Roden, R. B. S. & Stern, P. L. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat. Rev. Cancer 18, 240\u2013254 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"1208_CR8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222\u2013226 (2017).","journal-title":"Nature"},{"key":"1208_CR9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234\u2013239 (2019).","journal-title":"Nature"},{"key":"1208_CR10","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1208_CR11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1208_CR12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJMc2032195","volume":"384","author":"AT Widge","year":"2021","unstructured":"Widge, A. T. et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N. Engl. J. Med. 384, 80\u201382 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1208_CR13","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","volume":"385","author":"SJ Thomas","year":"2021","unstructured":"Thomas, S. J. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6\u2009months. N. Engl. J. Med. 385, 1761\u20131773 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1208_CR14","volume":"20","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. mRNA vaccine: a potential therapeutic strategy. Mol. Cancer 20, 33 (2021).","journal-title":"Mol. Cancer"},{"key":"1208_CR15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41551-019-0378-3","volume":"3","author":"KE Lindsay","year":"2019","unstructured":"Lindsay, K. E. et al. Visualization of early events in mRNA vaccine delivery in non-human primates via PET\u2013CT and near-infrared imaging. Nat. Biomed. Eng. 3, 371\u2013380 (2019).","journal-title":"Nat. Biomed. Eng."},{"key":"1208_CR16","volume":"119","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response. Proc. Natl Acad. Sci. USA 119, e2207841119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1208_CR17","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/cid\/ciab687","volume":"74","author":"MW Tenforde","year":"2022","unstructured":"Tenforde, M. W. et al. Effectiveness of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccines for preventing coronavirus disease 2019 hospitalizations in the United States. Clin. Infect. Dis. 74, 1515\u20131524 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"1208_CR18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41577-018-0088-1","volume":"19","author":"SC Eisenbarth","year":"2019","unstructured":"Eisenbarth, S. C. Dendritic cell subsets in T cell programming: location dictates function. Nat. Rev. Immunol. 19, 89\u2013103 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"1208_CR19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0092-8674(01)00455-X","volume":"106","author":"A Lanzavecchia","year":"2001","unstructured":"Lanzavecchia, A. & Sallusto, F. Regulation of T cell immunity by dendritic cells. Cell 106, 263\u2013266 (2001).","journal-title":"Cell"},{"key":"1208_CR20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2019.04.003","volume":"58","author":"WR Heath","year":"2019","unstructured":"Heath, W. R., Kato, Y., Steiner, T. M. & Caminschi, I. Antigen presentation by dendritic cells for B cell activation. Curr. Opin. Immunol. 58, 44\u201352 (2019).","journal-title":"Curr. Opin. Immunol."},{"key":"1208_CR21","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.4049\/jimmunol.161.3.1313","volume":"161","author":"M Wykes","year":"1998","unstructured":"Wykes, M., Pombo, A., Jenkins, C. & MacPherson, G. G. Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J. Immunol. 161, 1313\u20131319 (1998).","journal-title":"J. Immunol."},{"key":"1208_CR22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.coviro.2021.03.008","volume":"48","author":"BZ Igyarto","year":"2021","unstructured":"Igyarto, B. Z., Jacobsen, S. & Ndeupen, S. Future considerations for the mRNA-lipid nanoparticle vaccine platform. Curr. Opin. Virol. 48, 65\u201372 (2021).","journal-title":"Curr. Opin. Virol."},{"key":"1208_CR23","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMc2102131","volume":"384","author":"KG Blumenthal","year":"2021","unstructured":"Blumenthal, K. G. et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. N. Engl. J. Med. 384, 1273\u20131277 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1208_CR24","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41392-021-00759-1","volume":"6","author":"Y Yu","year":"2021","unstructured":"Yu, Y. et al. Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients. Signal Transduct. Target. Ther. 6, 346 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1208_CR25","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.cellsig.2010.03.018","volume":"22","author":"U Svajger","year":"2010","unstructured":"Svajger, U., Anderluh, M., Jeras, M. & Obermajer, N. C-type lectin DC-SIGN: an adhesion, signalling and antigen-uptake molecule that guides dendritic cells in immunity. Cell. Signal. 22, 1397\u20131405 (2010).","journal-title":"Cell. Signal."},{"key":"1208_CR26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nbt1390","volume":"26","author":"L Yang","year":"2008","unstructured":"Yang, L. et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol. 26, 326\u2013334 (2008).","journal-title":"Nat. Biotechnol."},{"key":"1208_CR27","doi-asserted-by":"crossref","first-page":"eabb2507","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, eabb2507 (2020).","journal-title":"Science"},{"key":"1208_CR28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41587-020-00781-8","volume":"39","author":"D Yin","year":"2021","unstructured":"Yin, D. et al. Targeting herpes simplex virus with CRISPR-Cas9 cures herpetic stromal keratitis in mice. Nat. Biotechnol. 39, 567\u2013577 (2021).","journal-title":"Nat. Biotechnol."},{"key":"1208_CR29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41551-020-00656-y","volume":"5","author":"S Ling","year":"2021","unstructured":"Ling, S. et al. Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice. Nat. Biomed. Eng. 5, 144\u2013156 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"1208_CR30","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1126\/science.abg6155","volume":"373","author":"M Segel","year":"2021","unstructured":"Segel, M. et al. Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery. Science 373, 882\u2013889 (2021).","journal-title":"Science"},{"key":"1208_CR31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","volume":"185","author":"S Banskota","year":"2022","unstructured":"Banskota, S. et al. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell 185, 250\u2013265.e16 (2022).","journal-title":"Cell"},{"key":"1208_CR32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1600-065X.2010.00967.x","volume":"239","author":"B Hu","year":"2011","unstructured":"Hu, B., Tai, A. & Wang, P. Immunization delivered by lentiviral vectors for cancer and infectious diseases. Immunol. Rev. 239, 45\u201361 (2011).","journal-title":"Immunol. Rev."},{"key":"1208_CR33","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1074\/mcp.R119.001491","volume":"18","author":"D Chang","year":"2019","unstructured":"Chang, D. & Zaia, J. Why glycosylation matters in building a better flu vaccine. Mol. Cell. Proteomics 18, 2348\u20132358 (2019).","journal-title":"Mol. Cell. Proteomics"},{"key":"1208_CR34","doi-asserted-by":"crossref","first-page":"eabb9983","DOI":"10.1126\/science.abb9983","volume":"369","author":"Y Watanabe","year":"2020","unstructured":"Watanabe, Y., Allen, J. D., Wrapp, D., McLellan, J. S. & Crispin, M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science 369, eabb9983 (2020).","journal-title":"Science"},{"key":"1208_CR35","doi-asserted-by":"crossref","first-page":"e0248348","DOI":"10.1371\/journal.pone.0248348","volume":"16","author":"SN Neerukonda","year":"2021","unstructured":"Neerukonda, S. N. et al. Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. PLoS ONE 16, e0248348 (2021).","journal-title":"PLoS ONE"},{"key":"1208_CR36","doi-asserted-by":"crossref","first-page":"e2005840","DOI":"10.1371\/journal.pbio.2005840","volume":"16","author":"B Wienert","year":"2018","unstructured":"Wienert, B., Shin, J., Zelin, E., Pestal, K. & Corn, J. E. In vitro-transcribed guide RNAs trigger an innate immune response via the RIG-I pathway. PLoS Biol. 16, e2005840 (2018).","journal-title":"PLoS Biol."},{"key":"1208_CR37","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1093\/nar\/gky177","volume":"46","author":"X Mu","year":"2018","unstructured":"Mu, X., Greenwald, E., Ahmad, S. & Hur, S. An origin of the immunogenicity of in vitro transcribed RNA. Nucleic Acids Res. 46, 5239\u20135249 (2018).","journal-title":"Nucleic Acids Res."},{"key":"1208_CR38","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.1128\/JVI.00912-14","volume":"88","author":"T Ying","year":"2014","unstructured":"Ying, T. et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J. Virol. 88, 7796\u20137805 (2014).","journal-title":"J. Virol."},{"key":"1208_CR39","first-page":"67","volume":"7","author":"ML Ma","year":"2021","unstructured":"Ma, M. L. et al. Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy. Cell Discov. 7, 67 (2021).","journal-title":"Cell Discov."},{"key":"1208_CR40","volume":"11","author":"HW Jiang","year":"2020","unstructured":"Jiang, H. W. et al. SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses. Nat. Commun. 11, 3581 (2020).","journal-title":"Nat. Commun."},{"key":"1208_CR41","volume":"34","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients. Cell Rep. 34, 108915 (2021).","journal-title":"Cell Rep."},{"key":"1208_CR42","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41422-020-00392-7","volume":"30","author":"J Lu","year":"2020","unstructured":"Lu, J. et al. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 30, 936\u2013939 (2020).","journal-title":"Cell Res."},{"key":"1208_CR43","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 15, 313\u2013320 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"1208_CR44","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","volume":"583","author":"L Bao","year":"2020","unstructured":"Bao, L. et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583, 830\u2013833 (2020).","journal-title":"Nature"},{"key":"1208_CR45","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nri3727","volume":"14","author":"W Kastenmuller","year":"2014","unstructured":"Kastenmuller, W., Kastenmuller, K., Kurts, C. & Seder, R. A. Dendritic cell-targeted vaccines\u2014hope or hype? Nat. Rev. Immunol. 14, 705\u2013711 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"1208_CR46","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1080\/14760584.2021.1988854","volume":"20","author":"M-W Ku","year":"2021","unstructured":"Ku, M.-W., Charneau, P. & Majlessi, L. Use of lentiviral vectors in vaccination. Expert Rev. Vaccines 20, 1571\u20131586 (2021).","journal-title":"Expert Rev. Vaccines"},{"key":"1208_CR47","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/CJI.0000000000000183","volume":"40","author":"SM Pollack","year":"2017","unstructured":"Pollack, S. M. et al. First-in-human treatment with a dendritic cell-targeting lentiviral vector-expressing NY-ESO-1, LV305, induces deep, durable response in refractory metastatic synovial sarcoma patient. J. Immunother. 40, 302\u2013306 (2017).","journal-title":"J. Immunother."},{"key":"1208_CR48","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s42003-021-02251-6","volume":"4","author":"MW Ku","year":"2021","unstructured":"Ku, M. W. et al. Lentiviral vector induces high-quality memory T cells via dendritic cells transduction. Commun. Biol. 4, 713 (2021).","journal-title":"Commun. Biol."},{"key":"1208_CR49","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.chom.2020.12.010","volume":"29","author":"MW Ku","year":"2021","unstructured":"Ku, M. W. et al. Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models. Cell Host Microbe 29, 236\u2013249.e6 (2021).","journal-title":"Cell Host Microbe"},{"key":"1208_CR50","first-page":"243","volume":"7","author":"TD Norton","year":"2016","unstructured":"Norton, T. D. & Miller, E. A. Recent advances in lentiviral vaccines for HIV-1 infection. Front. Immunol. 7, 243 (2016).","journal-title":"Front. Immunol."},{"key":"1208_CR51","doi-asserted-by":"publisher","unstructured":"Zhong, Y. SD_FIG1-7.xlsx.xlsx. figshare https:\/\/doi.org\/10.6084\/m9.figshare.24516694 (2023).","DOI":"10.6084\/m9.figshare.24516694"}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-024-01208-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-024-01208-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-024-01208-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T23:03:27Z","timestamp":1740006207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-024-01208-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["1208"],"URL":"https:\/\/doi.org\/10.1038\/s41551-024-01208-4","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]},"assertion":[{"value":"21 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.C. is a co-founder and advisor of BDGENE Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}